These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25372076)

  • 1. Reimbursement and adoption of advanced therapies: the 5-C framework.
    Malik NN
    Regen Med; 2014; 9(5):573-8. PubMed ID: 25372076
    [No Abstract]   [Full Text] [Related]  

  • 2. Centre for Commercialization of Regenerative Medicine: moving forward with regenerative medicine commercialization in Canada.
    Johnson S
    Stem Cells Dev; 2013 Dec; 22 Suppl 1():85-8. PubMed ID: 24304082
    [No Abstract]   [Full Text] [Related]  

  • 3. Bringing regenerative medicines to the clinic: the future for regulation and reimbursement.
    Bubela T; McCabe C; Archibald P; Atkins H; Bradshaw SE; Kefalas P; Mujoomdar M; Packer C; Piret J; Raxworthy M; Soares M; Viswanathan S
    Regen Med; 2015; 10(7):897-911. PubMed ID: 26565607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Social effects in regenerative medicine].
    Miyake J
    Nihon Rinsho; 2008 May; 66(5):1004-12. PubMed ID: 18464524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regenerative medicine: future impact on clinical therapies and society.
    Kargul J; Laurent GJ; Irminger-Finger I
    Int J Biochem Cell Biol; 2014 Nov; 56():1. PubMed ID: 25461768
    [No Abstract]   [Full Text] [Related]  

  • 6. Tissue engineering/regenerative medicine ventures should invest early in market research to understand the future market's needs.
    Gemmiti C
    Tissue Eng Part B Rev; 2013 Apr; 19(2):97-8. PubMed ID: 23327734
    [No Abstract]   [Full Text] [Related]  

  • 7. Regenerative medicine 2.0.
    Mason C
    Regen Med; 2007 Jan; 2(1):11-8. PubMed ID: 17465770
    [No Abstract]   [Full Text] [Related]  

  • 8. Turning Regenerative Medicine Breakthrough Ideas and Innovations into Commercial Products.
    Bayon Y; Vertès AA; Ronfard V; Culme-Seymour E; Mason C; Stroemer P; Najimi M; Sokal E; Wilson C; Barone J; Aras R; Chiesi A
    Tissue Eng Part B Rev; 2015 Dec; 21(6):560-71. PubMed ID: 26179129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Netherlands advancing to the forefront of regenerative medicine.
    Gielen K
    Stem Cells Dev; 2014 Dec; 23 Suppl 1():29-31. PubMed ID: 25457958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current understanding and challenges in bioprocessing of stem cell-based therapies for regenerative medicine.
    Ratcliffe E; Thomas RJ; Williams DJ
    Br Med Bull; 2011; 100():137-55. PubMed ID: 21852279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regenerative medicine and the developing world.
    Greenwood HL; Singer PA; Downey GP; Martin DK; Thorsteinsdóttir H; Daar AS
    PLoS Med; 2006 Sep; 3(9):e381. PubMed ID: 16968130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commercialization of regenerative medicine: learning from spin-outs.
    French A; Buckler RL; Brindley DA
    Rejuvenation Res; 2013 Apr; 16(2):164-70. PubMed ID: 23470045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. REIMBURSEMENT OF CELL-BASED REGENERATIVE THERAPY IN THE UK AND FRANCE.
    Mahalatchimy A
    Med Law Rev; 2016; 24(2):234-58. PubMed ID: 27083495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
    Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
    Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achieving reimbursement for regenerative medicine products in the USA.
    Ginty PJ; Singh PB; Smith D; Hourd P; Williams DJ
    Regen Med; 2010 May; 5(3):463-9. PubMed ID: 20455656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dangers in adopting a tissue-engineering-centric agenda: a president's perspective.
    Gilbert JL
    J Biomed Mater Res A; 2011 Feb; 96(2):273-4. PubMed ID: 21171146
    [No Abstract]   [Full Text] [Related]  

  • 17. Lancet Commission: Stem cells and regenerative medicine.
    Cossu G; Birchall M; Brown T; De Coppi P; Culme-Seymour E; Gibbon S; Hitchcock J; Mason C; Montgomery J; Morris S; Muntoni F; Napier D; Owji N; Prasad A; Round J; Saprai P; Stilgoe J; Thrasher A; Wilson J
    Lancet; 2018 Mar; 391(10123):883-910. PubMed ID: 28987452
    [No Abstract]   [Full Text] [Related]  

  • 18. Opening the gateways to market and adoption of regenerative medicine? The UK case in context.
    Faulkner A
    Regen Med; 2016 Apr; 11(3):321-30. PubMed ID: 27035398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenges of product development and commercialization in a convergence technology world: focus on regenerative medicine.
    Tozer D
    Drug Discov Today; 2010 Aug; 15(15-16):587-9. PubMed ID: 20546921
    [No Abstract]   [Full Text] [Related]  

  • 20. Cell therapy--back on the up-curve. Interview with Paul Kemp by Elisa Manzotti.
    Kemp P
    Regen Med; 2006 Jan; 1(1):9-14. PubMed ID: 17465816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.